We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Crossject | EU:ALCJ | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.09 | -4.81% | 1.78 | 1.776 | 1.796 | 1.892 | 1.752 | 1.88 | 126,177 | 12:36:31 |
Dijon, France, February 1, 2024 -- 18:15 CET - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a conference call on its commercial strategy in the U.S. and Europe on February 6, 2024 at 17:30 CET. The presentation will be held in English.
Patrick Alexandre, Crossject’s CEO and Executive Chairman, and Olivier Gire, COO of Specialty Pharma, will provide a business update following the January 4th announcement about entering into a strategic partnership with Syneos Health, a leading fully integrated biopharmaceutical solutions organization, to prepare for the commercial launch of Crossject’s ZEPIZURE® innovative rescue therapy for epileptic seizures in the U.S.
The leadership will also provide a general business update and discuss the Company’s progress towards its strategic objectives.
To register for the webcast, please use the following details:
https://us06web.zoom.us/webinar/register/WN_NcTN4As6R0i483uALLXFgw
Webcast recording will be available after the event.
About Crossject
Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, anepileptic rescue therapy, for which it was awarded a $60 million contract with the U.S.Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscularinjection on bare skin or even through clothing. The Company’s other products in developmentinclude rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthmaattacks.
For further information, please contact:
Investors Natasha DrapeauCohesion Bureau+41 76 823 75 27natasha.drapeau@cohesionbureau.com | MediaSophie BaumontCohesion Bureau+33 6 27 74 74 49sophie.baumont@cohesionbureau.com |
Attachment
1 Year Crossject Chart |
1 Month Crossject Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions